Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Henry Vanbrocklin, PhD
/
Publications
Henry Vanbrocklin, PhD's Publications
Computational Modeling to Advance Novel Medical Isotopes for Radiotheranostics: A DOE-NIH Joint Workshop Executive Summary.
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals.
First-in-human healthy volunteer dosimetry studies of the excitatory amino acid transporter 2 (EAAT2) PET imaging tracer methyl N4-(7-[18F]fluoro-9H-fluoren-2-yl)asparaginate, [18F]RP-115.
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer.
Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations.
Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals".
A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model.
A Feasibility Study of [18F]F-AraG Positron Emission Tomography (PET) for Cardiac Imaging-Myocardial Viability in Ischemia-Reperfusion Injury Model.
Actinium-225 targeted alpha particle therapy for prostate cancer.
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
Millimeter-scale radioluminescent power for electronic sensors.
PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.
[11C]Paraoxon: Radiosynthesis, Biodistribution and In Vivo Positron Emission Tomography Imaging in Rat.
[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue.
A feasibility study for quantitative assessment of cerebrovascular malformations using flutriciclamide ([18F]GE-180) PET/MRI.
Author Correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC).
Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac α-Radiotherapeutics.
Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19.
Organ-specific fuel rewiring in acute and chronic hypoxia redistributes glucose and fatty acid metabolism.
PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC).
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers.
Evaluating Radioactive Analogs of Doxorubicin to Quantify ChemoFilter Binding and Whole-Body Positron Emission Tomography/Magnetic Resonance Imaging for Drug Biodistribution.
First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody.
Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans.
Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using 18F-FAraG PET and MRI.
Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.
A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography.
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms.
Biological Distribution and Metabolic Profiles of Carbon-11 and Fluorine-18 Tracers of VX- and Sarin-Analogs in Sprague-Dawley Rats.
PET/CT Imaging of Human TNFα Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis.
Positron emission tomography evaluation of oxime countermeasures in live rats using the tracer O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate [18 F]-VXS.
Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.
The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET.
Total-Body PET Imaging in Infectious Diseases.
Divergent synthesis of organophosphate [11C]VX- and [11C]Sarin-surrogates from a common set of starting materials.
Enzymatically Catalyzed Radiofluorination of Biomolecules.
High Enantiomeric Excess In-Loop Synthesis of d-[methyl-11C]Methionine for Use as a Diagnostic Positron Emission Tomography Radiotracer in Bacterial Infection.
Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.
PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89.
Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.
Seeing Is Believing: Nuclear Imaging of HIV Persistence.
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI.
Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
Quantification of 89 Zr-Iron oxide nanoparticle biodistribution using PET-MR and ultrashort TE sequences.
Radiosynthesis of O-(1-[18 F]fluoropropan-2-yl)-O-(4-nitrophenyl)methylphosphonate: A novel PET tracer surrogate of sarin.
Radiosynthesis, ex Vivo Biodistribution, and in Vivo Positron Emission Tomography Imaging Evaluations of [11C]2-Pyridinealdoxime Methiodide ([11C]2-PAM): A First-In-Class Antidote Tracer for Organophosphate Intoxication.
[11C]Para-Aminobenzoic Acid: A Positron Emission Tomography Tracer Targeting Bacteria-Specific Metabolism.
11C-L-methyl methionine dynamic PET/CT of skeletal muscle: response to protein supplementation compared to L-[ring 13C6] phenylalanine infusion with serial muscle biopsy.
A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.
An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer.
An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor.
Dicarboxylic acids as pH sensors for hyperpolarized 13C magnetic resonance spectroscopic imaging.
Imaging Active Infection in vivo Using D-Amino Acid Derived PET Radiotracers.
In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis.
Dynamic nuclear polarization of biocompatible (13)C-enriched carbonates for in vivo pH imaging.
Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.
Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles.
Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase.
Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
[(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice.
[(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography.
A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography.
Imaging active urokinase plasminogen activator in prostate cancer.
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography.
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen.
A boronate-caged [¹⁸F]FLT probe for hydrogen peroxide detection using positron emission tomography.
A novel fluorine-18 β-fluoroethoxy organophosphate positron emission tomography imaging tracer targeted to central nervous system acetylcholinesterase.
Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
Regulatory Requirements for PET Drug Production.
Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET.
Photons across medicine: relating optical and nuclear imaging.
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.
Accepting the torch.
Approach to assessing myocardial perfusion in rats using static [13N]-ammonia images and a small-animal PET.
Imaging a functional tumorigenic biomarker in the transformed epithelium.
In memoriam: Michael John Welch, Ph.D 1939-2012.
The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
FDA cGMP requirements for PET drugs.
Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes.
Myocardial uptake of 7'-(Z)-[(123)I]iodorotenone during vasodilator stress in dogs with critical coronary stenoses.
Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas.
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma.
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
CGMP for PET drugs: important steps to take now.
Design of targeted cardiovascular molecular imaging probes.
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.
Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.
Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction.
Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment.
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Introduction to special issue.
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.
Advancing molecular imaging from the laboratory to everyday practice.
Bruce H. Hasegawa, PhD, 1951-2008.
Development of an optimized activatable MMP-14 targeted SPECT imaging probe.
Session 2: strategies for fast-track technological development and regulatory issues.
Molecular imaging update: advances in MI of the brain.
Mitochondrial avid radioprobes. Preparation and evaluation of 7'(Z)-[125I]iodorotenone and 7'(Z)-[125I]iodorotenol.
Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
A new precursor for the preparation of 6-[18F]Fluoro-L-m-tyrosine ([18F]FMT): efficient synthesis and comparison of radiolabeling.
Exemption of radiopharmaceuticals from <797>.
Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl.
Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges.
No effect of age and estrogen on aromatic L- amino acid decarboxylase activity in rhesus monkey brain.
Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer: comparison with 99mTc-sestamibi.
A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism.
6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates.
PET studies of functional compensation in a primate model of Parkinson's disease.
Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter.
PET studies of cerebral glucose metabolism in conscious rhesus macaques.
Synthesis and tissue biodistribution of [omega-11C]palmitic acid. A novel PET imaging agent for cardiac fatty acid metabolism.
The synthesis of 7 alpha-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents.
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors.
Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors.
In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine.
Synthesis, radiolabeling and tissue distribution of 11 beta-fluoroalkyl- and 11 beta-fluoroalkoxy-substituted estrogens: target tissue uptake selectivity and defluorination of a homologous series of fluorine-18-labeled estrogens.
Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical deve
Fluorine-substituted corticosteroids: synthesis and evaluation as potential receptor-based imaging agents for positron emission tomography of the brain.
Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: selective receptor-based PET imaging agents.
20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies.
11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
Binding of 16 alpha-[18F]fluoro-17 beta-estradiol to alphafetoprotein in Sprague-Dawley female rats affects blood levels.
Synthesis and tissue distribution of fluorine-18 labeled trifluorohexadecanoic acids. Considerations in the development of metabolically blocked myocardial imaging agents.
